Literature DB >> 20133108

How much more effective do depot antipsychotics have to be compared to oral antipsychotics before they are prescribed?

Johannes Hamann1, Rosmarie Mendel, Stephan Heres, Stefan Leucht, Werner Kissling.   

Abstract

Antipsychotic depots are less frequently prescribed than oral compounds. In an experimental study involving N=106 psychiatrists we studied how much more effective with respect to relapse prevention depot antipsychotics have to be compared to oral antipsychotics before they are chosen for prescription. Most psychiatrists have to judge depot as clearly superior with respect to relapse prevention before they recommend it to patients. If psychiatrists judge depot as unpleasant for the patients and do not see much need for checking their patients' compliance they are less likely to prescribe depot. Other psychiatrist-related factors (e.g. age, gender, and work experience) did not influence attitudes toward depot. 2009 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20133108     DOI: 10.1016/j.euroneuro.2010.01.001

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  10 in total

1.  Evidence-based Shared-Decision-Making Assistant (SDM-assistant) for choosing antipsychotics: protocol of a cluster-randomized trial in hospitalized patients with schizophrenia.

Authors:  Stefan Leucht; Johannes Hamann; Spyridon Siafis; Nicola Bursch; Katharina Müller; Lisa Schmid; Florian Schuster; Jakob Waibel; Tri Huynh; Florian Matthes; Alessandro Rodolico; Peter Brieger; Markus Bühner; Stephan Heres
Journal:  BMC Psychiatry       Date:  2022-06-17       Impact factor: 4.144

2.  [Heavy users of inpatient services: a comparison of diagnostic subgroups].

Authors:  Hans Rittmannsberger; Anke Sulzbacher; Christian Foff; Thomas Zaunmüller
Journal:  Neuropsychiatr       Date:  2014-07-30

Review 3.  Paliperidone extended-release: does it have a place in antipsychotic therapy?

Authors:  Maximilian Gahr; Markus A Kölle; Carlos Schönfeldt-Lecuona; Peter Lepping; Roland W Freudenmann
Journal:  Drug Des Devel Ther       Date:  2011-03-11       Impact factor: 4.162

4.  Patient perspectives on use of long-acting antipsychotics in bipolar disorder: focus on risperidone injection.

Authors:  L Samalin; T Charpeaud; O Lorabi; Pm Llorca
Journal:  Patient Prefer Adherence       Date:  2010-09-07       Impact factor: 2.711

5.  Treatment discontinuation and clinical outcomes in the 1-year naturalistic treatment of patients with schizophrenia at risk of treatment nonadherence.

Authors:  Katarina Kelin; Timothy Lambert; Alan Jm Brnabic; Richard Newton; Wendy Ye; Raúl I Escamilla; Kuang-Peng Chen; Liana Don; William Montgomery; Jamie Karagianis; Haya Ascher-Svanum
Journal:  Patient Prefer Adherence       Date:  2011-05-09       Impact factor: 2.711

6.  Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness.

Authors:  Pierre Michel Llorca; Mocrane Abbar; Philippe Courtet; Sebastien Guillaume; Sylvie Lancrenon; Ludovic Samalin
Journal:  BMC Psychiatry       Date:  2013-12-20       Impact factor: 3.630

7.  Reasons for initiating long-acting antipsychotics in psychiatric practice: findings from the STAR Network Depot Study.

Authors:  Corrado Barbui; Federico Bertolini; Francesco Bartoli; Carmela Calandra; Camilla Callegari; Giuseppe Carrà; Armando D'Agostino; Claudio Lucii; Giovanni Martinotti; Daniele Mastromo; Daniele Moretti; Emiliano Monzani; Matteo Porcellana; Davide Prestia; Giovanni Ostuzzi
Journal:  Ther Adv Psychopharmacol       Date:  2020-12-22

8.  The Willingness of Community Psychiatric Management Physicians to Preferentially Recommend Long-Acting Injections in Beijing.

Authors:  Lefan Jin; Yun Chen; Junli Zhu; Qingzhi Huang; Bin Li; Ying Xu; Rui Xi; Wei Lu
Journal:  Front Public Health       Date:  2021-11-19

Review 9.  Bromperidol decanoate (depot) for schizophrenia.

Authors:  Marianna Purgato; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2012-11-14

Review 10.  Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia.

Authors:  Gabriel Kaplan; Julio Casoy; Jacqueline Zummo
Journal:  Patient Prefer Adherence       Date:  2013-11-13       Impact factor: 2.711

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.